Análisis De Minimización De Costos Del Uso De Trastuzumab Subcutáneo Frente A Trastuzumab Intravenoso En El Tratamiento De Cáncer De Mama Temprano En Mujeres Con Her2 Positivo Para Venezuela

Romero, M Ponce; Acero, Germán Darío Flórez; Huerfano, LM

doi:10.1016/j.jval.2015.09.271

Cited by 5 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results show that replacing trastuzumab IV by trastuzumab SC would result in a saving of € 121.6 per patient in active HCP time for a full 18-cycle treatment, consistent with studies conducted in Belgium, France, New Zealand, the United Kingdom, Germany, and Venezuela [ 25 – 30 ].…”

Section: Discussionsupporting

confidence: 85%

Cost minimization analysis of treatment with intravenous or subcutaneous trastuzumab in patients with HER2-positive breast cancer in Spain

et al. 2017

View full text Add to dashboard Cite

PurposeTo describe healthcare professional (HCP) and patient time and related costs associated with trastuzumab intravenous infusion (IV) and trastuzumab subcutaneous (SC) formulations in patients with HER2-positive early breast cancer.MethodsThis prospective, observational time, and motion study in three Spanish centers was run as a substudy of the PrefHer trial. We recorded active HCP time for trastuzumab SC and IV-related tasks and calculated HCP time as the mean sum of task times over 154 administrations (80 IV, 74 SC). We calculated mean patient infusion chair time and treatment room time. Staff costs were calculated using fully loaded salary costs based on Spanish salaries (€ 2012).ResultsThe transition from trastuzumab IV to SC led to a 50% reduction in active HCP time [27.2 min (95% CI 21.8–32.6) vs. 13.2 min (95% CI 8.9–17.5) per cycle]. Time savings resulted from avoiding IV catheter installation and removal, line flushing, and drug reconstitution. SC administration led to a fivefold reduction (78–85%) in chair time and a fourfold reduction (59–81%) in patient treatment room time, resulting in 24 h free-up time in the total treatment course (18 cycles). Total estimated direct costs were € 29,431.75 and € 28,452.12 for IV and SC, respectively, a saving of € 979.60 over a full treatment course.ConclusionsTrastuzumab SC provided substantial time savings for HCP and patients, and reduced staff costs vs. trastuzumab IV. Reducing the use of hospital facilities may result in further savings and improved quality of medical care.Electronic supplementary materialThe online version of this article (doi:10.1007/s12094-017-1684-4) contains supplementary material, which is available to authorized users.

show abstract

Section: Discussionsupporting

confidence: 85%

Cost minimization analysis of treatment with intravenous or subcutaneous trastuzumab in patients with HER2-positive breast cancer in Spain

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Lopez-Vivanco et al reported that SC-TZM provided a € 979.60 (USD $1,156) savings per patient versus IV-TZM; however, they did not assess costs associated with serious ADRs, and the criteria used to define patient weights for the calculation of load and maintenance doses were not reported [20]. A cost study performed in Latin America by Romero et al reported favorable figures for SC-TZM, but that study had the same shortcomings as the study by Lopez-Vivanco et al [21]. A review by Papadmitriou et al suggested a substantial economic benefit associated with SC-TZM versus IV-TZM; however, the evidence was somewhat limited (based on only two studies), and the resources employed across the different healthcare systems assessed were highly heterogeneous [22].…”

Section: Discussionmentioning

confidence: 99%

Cost-minimization analysis of subcutaneous versus intravenous trastuzumab administration in Chilean patients with HER2-positive early breast cancer

et al. 2020

View full text Add to dashboard Cite

Trastuzumab (TZM) improves survival and the risk of recurrence among patients with earlystage HER2+ breast cancer (BC). TZM treatment can be given intravenously (IV-TZM) or subcutaneously (SC-TZM). Although both methods have similar efficacy and safety, they differ in dosage and administration. Previous studies of cost minimization determined that SC-TZM is associated with lower costs than IV-TZM; however, those studies did not include the costs associated with body weight-based dosage and the treatment of adverse drug reactions (ADRs). Methods/Patients We performed a model-based cost-minimization analysis. The analysis included direct and indirect medical costs associated with TZM preparation (adjusted by body weight) and administration and also costs due to severe ADRs and non-medical costs that occurred during the total treatment course (18 cycles). We performed a sensitivity analysis to test the robustness of the results across various TZM costs and patient body weights.

show abstract

Cost Minimization Analysis of Intravenous or Subcutaneous Trastuzumab Treatment in Patients With HER2-Positive Breast Cancer in Ireland

O’Brien

O’Mahony

Cooke

et al. 2019

Clinical Breast Cancer

View full text Add to dashboard Cite

Análisis De Minimización De Costos Del Uso De Trastuzumab Subcutáneo Frente A Trastuzumab Intravenoso En El Tratamiento De Cáncer De Mama Temprano En Mujeres Con Her2 Positivo Para Venezuela

Cited by 5 publications

References 0 publications

Cost minimization analysis of treatment with intravenous or subcutaneous trastuzumab in patients with HER2-positive breast cancer in Spain

Cost minimization analysis of treatment with intravenous or subcutaneous trastuzumab in patients with HER2-positive breast cancer in Spain

Cost-minimization analysis of subcutaneous versus intravenous trastuzumab administration in Chilean patients with HER2-positive early breast cancer

Cost Minimization Analysis of Intravenous or Subcutaneous Trastuzumab Treatment in Patients With HER2-Positive Breast Cancer in Ireland

Contact Info

Product

Resources

About